Author(s) |
Zannad F, Kessler M, Grünfeld JP, Thuilliez C, and the FOSIDIAL Investigators
|
 |
Title(s) |
FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients’ baseline characteristics
|
|
Reference(s) |
Fundam Clin Pharmacol 2002;16:353-60
|
|
Disease |
Renal failure
|
|
Purpose |
To evaluate the efficacy and safety of fosinopril in reducing the incidence of fatal and nonfatal major cardiovascular events in haemodialysis patients with left ventricular hypertrophy
|
|
Study design |
Randomised, double-blind, placebo-controlled
|
|
Follow-up |
2 years
|
|
Patients |
397 patients, mean age 66.7 ± 8.04 years, undergoing haemodialysis for at least 6 months and with cardiac mass index > 131 g/m2 for men and > 100 g/m2 for women
|
|
Treatment regimen |
Fosinopril, 5-20 mg/day, or placebo
|
|
Results |
Not yet available
|
|
Comments |
Data on a risk prediction model based on the FOSIDIAL trial to identify factors predictive of cardiovascular events in patients with high-risk end-stage renal disease have been published in Nephrol Dial Transplant 2007;22:3573–79 |
|
